Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGPL1 | O95470 | 4/20 | 0.44 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 5/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSPO | P30536 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL9117264 | 0.82 | LAP3 (0.42) | SMPD1S1PR4S1PR1S1PR3S1PR2 | |
| SCHEMBL12766767 | 0.80 | SGPL1 (0.48) | SGPL1LPAR5SMPD1LPAR3LPAR1 | |
| SCHEMBL15892988 | 0.77 | SGPL1 (0.50) | SGPL1LPAR5SMPD1LPAR3LPAR1 | |
| SCHEMBL9113451 | 0.77 | SGPL1 (0.45) | SGPL1LPAR5SMPD1LPAR3LPAR1 | |
| SCHEMBL30718031 | 0.76 | SPHK1 (0.41) | — | |
| SCHEMBL9116836 | 0.76 | SPHK1 (0.41) | — | |
| SCHEMBL9245727 | 0.76 | SGPL1 (0.44) | SGPL1LPAR5SMPD1LPAR3LPAR1 | |
| SCHEMBL11325815 | 0.73 | SMPD1 (0.47) | SGPL1SMPD1LPAR3LPAR1LPAR2 | |
| Phosphoric Acid SCHEMBL2806140 | 0.71 | LAP3 (0.53) | SMPD1S1PR4S1PR1S1PR3S1PR2 | |
| Phosphoric Acid SCHEMBL670802 | 0.71 | LAP3 (0.53) | SMPD1S1PR4S1PR1S1PR3S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200261420-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BIOSCIENCE (CH) | 2020-08-20 | — | — | US | claimed |
| CN-111432815-A | Enhancing cancer treatment efficacy via sphingosine-1-phosphate pathway | AC生物科学公司 | 2020-07-17 | — | — | CN | claimed |
| EP-3668506-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BioScience (CH) | 2020-06-24 | — | — | EP | claimed |
| WO-2019034768-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BIOSCIENCE (CH) | 2019-02-21 | — | — | WO | claimed |
| US-11850234-B2 | Enhancement of cancer treatment efficiency via the sphingosine-1-phosphate pathway | AC BIOSCIENCE (CH) | 2023-12-26 | — | — | US | disclosed |
| US-20200261420-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BIOSCIENCE (CH) | 2020-08-20 | — | — | US | disclosed |
| CN-111432815-A | Enhancing cancer treatment efficacy via sphingosine-1-phosphate pathway | AC生物科学公司 | 2020-07-17 | — | — | CN | disclosed |
| EP-3668506-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BioScience (CH) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019034768-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BIOSCIENCE (CH) | 2019-02-21 | — | — | WO | disclosed |
| US-6692960-B2 | GENE EXPRESSION INHIBITION; TREATING DEVELOPMENTAL DISORDERS OR ABERRANT APOPTOSIS | ISIS PHARMACEUTICALS, INC. | 2004-02-17 | — | — | US | disclosed |
| US-20030092650-A1 | Antisense modulation of sphingosine-1-phosphate lyase expression | ISIS PHARMACEUTICALS INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2003028637-A2 | ANTISENSE MODULATION OF SPHINGOSINE-1-PHOSPHATE LYASE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-04-10 | — | — | WO | disclosed |
| WO-1995021848-A1 | SPHINGOID BASES AND METHODS FOR THEIR PREPARATION AND USE | THE UNITED STATES OF AMERICA, REPRESENTED BY THE (US) | 1995-08-17 | — | — | WO | disclosed |
| US-5430169-A | Method for preparation of sphingoid bases | THE UNITED STATES OF AMERICA REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11850234-B2 | Enhancement of cancer treatment efficiency via the sphingosine-1-phosphate pathway | SPHK1, S1PR1, S1PR2 | SGPL1 7/4885LPAR5 251/4885SMPD1 9/4885 |
| US-20200261420-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | SPHK1, S1PR1, S1PR2 | SGPL1 7/4885LPAR5 251/4885SMPD1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.